CALR抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Hela cells, 293T cells, NIH/3T3 cells, Primary antibody: P07330(CALR Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P07330(CALR Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07330(CALR Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

CALR antibodies are associated with mutations in the calreticulin (CALR) gene, primarily identified in myeloproliferative neoplasms (MPNs), a group of blood disorders characterized by abnormal bone marrow cell proliferation. CALR is a chaperone protein located in the endoplasmic reticulum, involved in calcium homeostasis and glycoprotein folding. In 2013. recurrent somatic mutations in CALR were discovered in MPN patients lacking JAK2 or MPL mutations, marking a breakthrough in understanding MPN genetics.

Approximately 25-30% of essential thrombocythemia and primary myelofibrosis cases harbor CALR mutations. These mutations, typically exon 9 insertions or deletions, generate a novel C-terminal peptide sequence that alters CALR's structure and function. Mutant CALR proteins exhibit oncogenic potential through constitutive activation of the thrombopoietin receptor (MPL) and JAK-STAT signaling pathways, driving uncontrolled megakaryocyte proliferation.

CALR antibodies are detected using ELISA or immunoassays and serve as biomarkers for diagnosis and monitoring. They specifically target mutant CALR isoforms, distinguishing them from wild-type proteins. Their presence correlates with distinct clinical features, including lower thrombotic risk compared to JAK2-mutated MPNs. Research continues to explore their role in disease mechanisms and potential therapeutic targeting.